secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-01-28T23:59:59+00:00
Accession:  0001823239-22-000006
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics
--------------------------------------------------------------------------------

- Purchase price $240M cash at close plus contingent consideration based on future conditions.
- MyChem provides ultra-pure nucleotides for diagnostics, pharma, genomics; complements Maravai's TriLink mRNA technologies.
- MyChem to become part of TriLink's Nucleic Acid Production segment; founder-led team stays on.
- Deal strengthens Maravai's end-to-end mRNA supply chain and adds GMP manufacturing capability.
- Advisors: Jefferies & Kirkland & Ellis for Maravai; BroadOak & Morrison & Foerster for MyChem.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000006/0001823239-22-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000006/mrvi-20220128.htm
  HTML page:      https://secwatch.observer/filing/0001823239-22-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer